Insight Molecular Diagnostics (IMDX) Cash from Investing Activities (2015 - 2026)

Insight Molecular Diagnostics has disclosed Cash from Investing Activities across 12 years of filings, most recently posting -$613000.0 for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$613000.0, down 99.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.5 million (down 339.12% YoY), and the FY2025 annual result was -$3.2 million, down 522.07% from the prior year.
• Cash from Investing Activities came in at -$613000.0 for Q1 2026 at Insight Molecular Diagnostics, up from -$1.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $214000.0 in Q3 2023 to a low of -$1.6 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is -$349000.0 (2025), against an average of -$563647.1.
• Across the five-year window, Cash from Investing Activities jumped 124.91% in 2023 and plunged 1179.17% in 2025, its largest moves.
• Insight Molecular Diagnostics' Cash from Investing Activities stood at -$802000.0 in 2022, then jumped by 112.84% to $103000.0 in 2023, then plunged by 303.88% to -$210000.0 in 2024, then slumped by 604.29% to -$1.5 million in 2025, then surged by 58.55% to -$613000.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$613000.0 (Q1 2026), -$1.5 million (Q4 2025), and -$1.0 million (Q3 2025), per Business Quant data.